ADDISON, Texas, March 11, 2015 /PRNewswire/ -- ULURU
Inc. (OTCQB: ULUR) announced today the extension to
December 31, 2015 of the option
granted to OraDisc GmbH for the use of our OraDisc™ technology for
drug delivery. The therapeutic categories covered by the agreement
have been expanded to include anti-psychotics, neurologics and
erectile dysfunction.
The global drug delivery market expanded from $127 billion in 2010 to $143 billion in 2012 with anticipated growth to
$224 billion in 2017. The market for
transmucosal drug delivery is approximately 4% of the global drug
delivery market with a forecast of approximately $9.0 billion in 2017.
The OraDisc™ technology is a unique, patent protected
multi-layer mucoadhesive drug delivery technology designed to
delivery drugs systemically across the mucosal surface.
OraDisc™ causes minimum discomfort, is easy to apply and capable of
providing tailored erosion rates to delivery therapeutics over
different time intervals. The erosion time can be easily regulated,
from 15 minutes to over three hours, simply by compositional
changes and /or coating thickness.
Development activities have commenced with four compounds that
have recently lost patent protection or the patent will expire
within the next 24 months. One potential advantage of the OraDisc™
technology is to extend the period of patent protection.
Upon patent expiration, products experience a decrease in sales
between 70% to 80% due to the generic competition. The selected
development candidates are compounds which are block busters in
their therapeutic categories; antipsychotic, neurologics, erectile
dysfunction and analgesics.
The global erectile dysfunction drug market is valued at
approximately $4.3 billion. The
chosen candidates within the psychotic and neurologic market
currently have annual sales of approximately $7.5 billion and $4.0
billion.
Commenting on the option extension, Dr. Josef Doppler, Director of OraDisc GmbH stated
"Extensive review has been undertaken with potential strategic
partners and the medical community to identify the appropriate
therapeutic categories and actives to take maximum advantage of the
OraDisc™ technology. We are excited with the potential to develop a
range of products utilizing this mucoadhesive drug delivery
technology. Development programs have been initiated to move these
projects forward."
Studies have been conducted which demonstrate the effectiveness
of the OraDisc™ technology as a drug delivery vehicle. Compared to
oral tablet formulations in preclinical studies OraDisc™ was able
to achieve at equal doses a maximum blood concentration 80% higher
and deliver in excess of 130% more drug in the same time period. In
addition, depending on the formulation characteristics used drug
delivery can be easily regulated. These characteristics plus rapid
onset of drug action and avoidance of first pass metabolism make
the OraDisc™ technology well suited to the chosen therapeutic
categories with the potential for superior clinical
performance.
About ULURU Inc.:
ULURU Inc. is a specialty
pharmaceutical company focused on the development of a portfolio of
wound management and oral care products to provide patients and
consumers improved clinical outcomes through controlled delivery
utilizing its innovative Nanoflex® Aggregate technology
and OraDisc™ transmucosal delivery system. For further
information about ULURU Inc., please visit our website at
www.uluruinc.com. For further information about
Altrazeal®, please visit www.Altrazeal.com.
ULURU Inc. (OTCQB: ULUR) trades on the OTCQB Venture stage
marketplace for early stage and developing U.S. and international
companies. Companies are current in their reporting and undergo an
annual verification and management certification process. Investors
can find Real-Time quotes and market information for the company on
www.otcmarkets.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended. These statements are subject to
numerous risks and uncertainties, including but not limited to the
advantages of the OraDisc™ technology, regulation of drug
delivery , potential to develop a range of products and the risk
factors detailed in the Company's Annual Report on Form 10-K for
the year ended December 31, 2013, and
other reports filed by us with the Securities and Exchange
Commission.
Contact: Company
Kerry P.
Gray
President & CEO
Terry K. Wallberg
Vice President &
CFO
(214) 905-5145
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/uluru-inc-announces-the-extension-and-expansion-of-the-option-granted-to-oradisc-gmbh-300049076.html
SOURCE ULURU Inc.